drug_type
RELEVANT_DRUG
intervention_type
Gene therapy (viral vector, in vivo CAR)
drug_description
In vivo gene therapy delivered by viral vector to transduce patient immune cells to express an anti-CD19 CAR-like receptor, activating T-cell signaling to kill CD19+ B cells; administered IV or via splenic artery/lymph node.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Gene Therapy
drug_category
GENE THERAPY
drug_class
Gene therapy
drug_delivery_route
Intravenous, Intra-arterial, Intra-lymphatic
drug_mechanism_of_action
Viral vector delivered in vivo transduces the patient's T cells to express an anti-CD19 CAR-like receptor. Upon binding CD19 on B cells, the engineered T cells activate CAR signaling, expand, and kill CD19-positive malignant B cells, resulting in on-target B-cell depletion.
drug_name
JY231
nct_id_drug_ref
NCT06514768